FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891713080> ?p ?o ?g. }

• W2891713080 endingPage "2207" @default.
• W2891713080 startingPage "2196" @default.
• W2891713080 abstract "Essentials•Factor IX (FIX) dosing using body weight frequently results in under and overdosing during surgery.•We aimed to establish a population pharmacokinetic (PK) model describing the perioperative FIX levels.•Population PK parameter values for clearance and V1 were 284 mL h−170 kg−1 and 5450 mL70 kg−1.•Perioperative PK parameters differ from those during non‐surgical prophylactic treatment.Summary: BackgroundHemophilia B is a bleeding disorder characterized by a deficiency of coagulation factor IX (FIX). In the perioperative setting, patients receive FIX concentrates to ensure hemostasis. Although FIX is usually dosed according to bodyweight, under‐ and overdosing occurs frequently during surgery.AimThe objective was to quantify and explain the interpatient variability of perioperatively administered plasma‐derived (pd) and recombinant (r) FIX concentrates.MethodsData were collected from 118 patients (median age, 40 years [range, 0.2–90]; weight, 79 kg [range, 5.3–132]) with moderate (28%) or severe hemophilia B (72%), undergoing 255 surgical procedures. Population pharmacokinetic (PK) parameters were estimated using nonlinear mixed‐effect modeling in NONMEM.ResultsMeasured perioperative FIX level vs. time profiles were adequately described using a three‐compartment PK model. For a typical 34‐year‐old patient receiving rFIX, clearance (CL), intercompartmental clearance (Q2, Q3), distribution volume of the central compartment (V1) and peripheral compartments (V2, V3) plus interpatient variability (%CV) were: CL, 284 mL h−170 kg−1 (18%); V1, 5450 mL70 kg−1 (19%); Q2, 110 mL h−170 kg−1; V2, 4800 mL70 kg−1; Q3, 1610 mL h−170 kg−1; V3, 2040 mL70 kg−1. From 0.2 years, CL and V1 decreased 0.89% and 1.15% per year, respectively, until the age of 34 years. Patients receiving pdFIX exhibited a lower CL (11%) and V1 (17%) than patients receiving rFIX. Interpatient variability was successfully quantified and explained.ConclusionsThe estimated perioperative PK parameters of both pdFIX and rFIX are different from those reported for prophylactic treatment. The developed model may be used to apply PK‐guided dosing of FIX concentrates during surgery. Essentials•Factor IX (FIX) dosing using body weight frequently results in under and overdosing during surgery.•We aimed to establish a population pharmacokinetic (PK) model describing the perioperative FIX levels.•Population PK parameter values for clearance and V1 were 284 mL h−170 kg−1 and 5450 mL70 kg−1.•Perioperative PK parameters differ from those during non‐surgical prophylactic treatment. •Factor IX (FIX) dosing using body weight frequently results in under and overdosing during surgery.•We aimed to establish a population pharmacokinetic (PK) model describing the perioperative FIX levels.•Population PK parameter values for clearance and V1 were 284 mL h−170 kg−1 and 5450 mL70 kg−1.•Perioperative PK parameters differ from those during non‐surgical prophylactic treatment. Hemophilia B is a bleeding disorder characterized by a deficiency of coagulation factor IX (FIX). In the perioperative setting, patients receive FIX concentrates to ensure hemostasis. Although FIX is usually dosed according to bodyweight, under‐ and overdosing occurs frequently during surgery. The objective was to quantify and explain the interpatient variability of perioperatively administered plasma‐derived (pd) and recombinant (r) FIX concentrates. Data were collected from 118 patients (median age, 40 years [range, 0.2–90]; weight, 79 kg [range, 5.3–132]) with moderate (28%) or severe hemophilia B (72%), undergoing 255 surgical procedures. Population pharmacokinetic (PK) parameters were estimated using nonlinear mixed‐effect modeling in NONMEM. Measured perioperative FIX level vs. time profiles were adequately described using a three‐compartment PK model. For a typical 34‐year‐old patient receiving rFIX, clearance (CL), intercompartmental clearance (Q2, Q3), distribution volume of the central compartment (V1) and peripheral compartments (V2, V3) plus interpatient variability (%CV) were: CL, 284 mL h−170 kg−1 (18%); V1, 5450 mL70 kg−1 (19%); Q2, 110 mL h−170 kg−1; V2, 4800 mL70 kg−1; Q3, 1610 mL h−170 kg−1; V3, 2040 mL70 kg−1. From 0.2 years, CL and V1 decreased 0.89% and 1.15% per year, respectively, until the age of 34 years. Patients receiving pdFIX exhibited a lower CL (11%) and V1 (17%) than patients receiving rFIX. Interpatient variability was successfully quantified and explained. The estimated perioperative PK parameters of both pdFIX and rFIX are different from those reported for prophylactic treatment. The developed model may be used to apply PK‐guided dosing of FIX concentrates during surgery." @default.
• W2891713080 created "2018-09-27" @default.
• W2891713080 creator A5002870795 @default.
• W2891713080 creator A5003775399 @default.
• W2891713080 creator A5021986417 @default.
• W2891713080 creator A5022826294 @default.
• W2891713080 creator A5032240160 @default.
• W2891713080 creator A5034484228 @default.
• W2891713080 creator A5038337189 @default.
• W2891713080 creator A5043026808 @default.
• W2891713080 creator A5049795850 @default.
• W2891713080 creator A5051750476 @default.
• W2891713080 creator A5063885274 @default.
• W2891713080 creator A5064355731 @default.
• W2891713080 creator A5065311756 @default.
• W2891713080 creator A5069096181 @default.
• W2891713080 creator A5079993239 @default.
• W2891713080 date "2018-11-01" @default.
• W2891713080 modified "2023-10-17" @default.
• W2891713080 title "Population pharmacokinetics of factor IX in hemophilia B patients undergoing surgery" @default.
• W2891713080 cites W1564744230 @default.
• W2891713080 cites W1973891097 @default.
• W2891713080 cites W1986601719 @default.
• W2891713080 cites W1991924448 @default.
• W2891713080 cites W1993147091 @default.
• W2891713080 cites W2005069607 @default.
• W2891713080 cites W2013607072 @default.
• W2891713080 cites W2020123164 @default.
• W2891713080 cites W2023806093 @default.
• W2891713080 cites W2042553471 @default.
• W2891713080 cites W2054251743 @default.
• W2891713080 cites W2064718783 @default.
• W2891713080 cites W2065039877 @default.
• W2891713080 cites W2072098181 @default.
• W2891713080 cites W2076217357 @default.
• W2891713080 cites W2078887465 @default.
• W2891713080 cites W2093123260 @default.
• W2891713080 cites W2106173868 @default.
• W2891713080 cites W2120416054 @default.
• W2891713080 cites W2120973506 @default.
• W2891713080 cites W2135468468 @default.
• W2891713080 cites W2145263073 @default.
• W2891713080 cites W2284600747 @default.
• W2891713080 cites W2466900511 @default.
• W2891713080 cites W2732589685 @default.
• W2891713080 cites W2741244345 @default.
• W2891713080 cites W4232102811 @default.
• W2891713080 doi "https://doi.org/10.1111/jth.14292" @default.
• W2891713080 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30394056" @default.
• W2891713080 hasPublicationYear "2018" @default.
• W2891713080 type Work @default.
• W2891713080 sameAs 2891713080 @default.
• W2891713080 citedByCount "11" @default.
• W2891713080 countsByYear W28917130802020 @default.
• W2891713080 countsByYear W28917130802021 @default.
• W2891713080 countsByYear W28917130802022 @default.
• W2891713080 countsByYear W28917130802023 @default.
• W2891713080 crossrefType "journal-article" @default.
• W2891713080 hasAuthorship W2891713080A5002870795 @default.
• W2891713080 hasAuthorship W2891713080A5003775399 @default.
• W2891713080 hasAuthorship W2891713080A5021986417 @default.
• W2891713080 hasAuthorship W2891713080A5022826294 @default.
• W2891713080 hasAuthorship W2891713080A5032240160 @default.
• W2891713080 hasAuthorship W2891713080A5034484228 @default.
• W2891713080 hasAuthorship W2891713080A5038337189 @default.
• W2891713080 hasAuthorship W2891713080A5043026808 @default.
• W2891713080 hasAuthorship W2891713080A5049795850 @default.
• W2891713080 hasAuthorship W2891713080A5051750476 @default.
• W2891713080 hasAuthorship W2891713080A5063885274 @default.
• W2891713080 hasAuthorship W2891713080A5064355731 @default.
• W2891713080 hasAuthorship W2891713080A5065311756 @default.
• W2891713080 hasAuthorship W2891713080A5069096181 @default.
• W2891713080 hasAuthorship W2891713080A5079993239 @default.
• W2891713080 hasBestOaLocation W28917130801 @default.
• W2891713080 hasConcept C112705442 @default.
• W2891713080 hasConcept C126322002 @default.
• W2891713080 hasConcept C126894567 @default.
• W2891713080 hasConcept C139254425 @default.
• W2891713080 hasConcept C141071460 @default.
• W2891713080 hasConcept C2776239304 @default.
• W2891713080 hasConcept C2777288759 @default.
• W2891713080 hasConcept C2781221834 @default.
• W2891713080 hasConcept C2908647359 @default.
• W2891713080 hasConcept C3020755252 @default.
• W2891713080 hasConcept C31174226 @default.
• W2891713080 hasConcept C42219234 @default.
• W2891713080 hasConcept C71924100 @default.
• W2891713080 hasConcept C99454951 @default.
• W2891713080 hasConceptScore W2891713080C112705442 @default.
• W2891713080 hasConceptScore W2891713080C126322002 @default.
• W2891713080 hasConceptScore W2891713080C126894567 @default.
• W2891713080 hasConceptScore W2891713080C139254425 @default.
• W2891713080 hasConceptScore W2891713080C141071460 @default.
• W2891713080 hasConceptScore W2891713080C2776239304 @default.
• W2891713080 hasConceptScore W2891713080C2777288759 @default.
• W2891713080 hasConceptScore W2891713080C2781221834 @default.
• W2891713080 hasConceptScore W2891713080C2908647359 @default.
• W2891713080 hasConceptScore W2891713080C3020755252 @default.

• next